A research position in basic & translational breast cancer research at Northwestern University

Location
Chicago, Illinois
Salary
NIH scale
Posted
May 09 2017
Ref
Translational cancer research at Northwestern Univ
Position Type
Full Time
Organization Type
Academia

A research position (Ph.D. level or equivalent) is available in a relatively newer breast cancer research lab (Dai Horiuchi, Principal Investigator) at Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center in Chicago.

The primary focus of the lab is to study the mechanisms of tumor progression in breast cancer and to identify novel targeted treatment strategies. To achieve these goals, we utilize a collection of human breast cancer cell lines, preclinical animal models, primary tumor organoids ex vivo, and high-throughput screening approaches along with state-of-the-art bioinformatics through collaboration with experts in the field. We are determined to help bring basic laboratory findings to clinical testing, and our research involves dynamic interactions with clinicians here at Northwestern Medicine and industry partners.

We are devoted to understanding the cellular events that influence the aggressiveness of breast tumors with our emphasis on the triple-negative breast cancer (TNBC) subtype, and are currently focused on the following areas:

  • Mechanisms of tumor progression mediated by proto-oncogenes (i.e., MYC transcription factor, PIM family of serine/threonine kinases, among others), their activators and effectors, and tumor microenvironment.
  • Therapeutic targetability of novel molecular factors, including the modulators of microenvironmental components, that significantly influence a patient clinical outcome.

    We are seeking a highly motivated, Ph.D. level researcher who is passionate about the concept of “personalized medicine.” Prior in-depth training in (breast) cancer research involving rodent animal models (e.g., transgenic/syngeneic/PDX) as demonstrated by peer-reviewed publications is a must for this position.

    For this round of recruitment, we are particularly interested in identifying a new team member in one of the following two research areas:

    (1) Preclinical validation of our lab identified targeted therapeutic strategies and their translation to early stage clinical testing in collaboration with clinicians. This project requires a familiarity with three-dimensional cell culture methods (e.g., Matrigel, spheres, primary organoids, co-culture) and high-throughput high-content screening approaches using BioTek Cytation 5 and Molecular Devices ImageXpress Micro Confocal System.

    (2) Functional studies focused on understanding the mechanisms by which an immune-suppressive TNBC microenvironment is generated and maintained. This project requires a Ph.D. or advanced training in immunology (with emphasis on T/NK cell biology). Solid understanding of the current literature in immuno-oncology would be valuable.

    In both (1) and (2), a solid understanding of fundamental global gene expression and statistical analysis methods is required. Also essential is an ability to communicate with others effectively and efficiently as this position requires constant communication with our collaborators on and off campus. This position is most suitable for an individual who is capable of functioning in a fast-paced environment independently with minimum guidance, and who wishes to embark on a career in pharmaceutical research.

    Overall cancer research at Northwestern is on an exciting, rapid growth phase and provides enormous opportunities for us to positively impact the lives of cancer patients through innovative basic and translational research. Please send an email with a brief introduction of your academic/research background and current career goals, curriculum vitae, and contact info for three references to Dai Horiuchi, Ph.D., Department of Pharmacology, R.H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine at horiuchilab123@gmail.com. Successful candidates will be contacted via email.